Last reviewed · How we verify
NCT06690593
Characteristics and Clinical Significance of Gut Microbiota in Patients With Monoclonal Gammopathy
trial in Monoclonal Gammopathy of Undetermined Significance (MGUS) in 2,990 participants. Currently enrolling.
30 June 2026
Quick facts
| Lead sponsor | Zhujiang Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 2,990 |
| Start date | 26 December 2024 |
| Primary completion | 30 June 2026 |
| Estimated completion | 30 December 2026 |
| Sites | 1 location across China |
Conditions studied
- Monoclonal Gammopathy of Undetermined Significance (MGUS) — all drugs for Monoclonal Gammopathy of Undetermined Significance (MGUS) →
- Intestinal Flora — all drugs for Intestinal Flora →
- Multiple Myeloma — all drugs for Multiple Myeloma →
- M-Protein — all drugs for M-Protein →
Sponsor
Zhujiang Hospital
Who can join
45 and older, any sex, with Monoclonal Gammopathy of Undetermined Significance (MGUS) or Intestinal Flora. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an observational case-control study, aiming to systematically analyze the gut microbiome characteristics of patients with monoclonal gammopathy of undetermined significance (MGUS). The study will collect blood and stool samples from MGUS patients, non-MGUS patients (with similar diseases), and healthy controls, and perform multi-omics detection including microbiomics, peptidomics, and biochemical immunology. It will comprehensively analyze the abnormal features of the gut microbiome in MGUS patients, which may help provide new biomarkers and potential mechanisms for the diagnosis, prognosis evaluation, and treatment strategies of MGUS.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06690593
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Monoclonal Gammopathy of Undetermined Significance (MGUS)
Currently open trials in the same condition.
- NCT06140524 — A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple My · Phase 2 · recruiting
- NCT07214324 — Integrative Multi-omics Analysis to Predict Monoclonal Gammopathies Clinical Evolution · active not recruiting
- NCT05283993 — A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH · recruiting
Other Zhujiang Hospital trials
Trials by the same sponsor.
- NCT07335094 — A Clinical Study of Humanized CD19 CAR-T Cells With TLR2 for the Treatment of Adult Patients With Naive B-Cell Acute Lym · EARLY_PHASE1 · not yet recruiting
- NCT07469072 — Comparison of Anticoagulant Effects of Different Doses of Nafamostat in Continuous Renal Replacement Therapy (CRRT) in t · Phase 2 · recruiting
- NCT07455149 — An Observational Clinical Study on the Association of Intestinal Ruminococcus Gnavus and Its Derived Biogenic Amines Wit · not yet recruiting
- NCT07457099 — Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Resectable Locally Advanced Oral a · not yet recruiting
- NCT07454421 — Racecadotril for Organ Injury in Sepsis Patients · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06690593 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhujiang Hospital
- Last refreshed: 27 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06690593.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing